The statement adds that the company's goal "is to make remdesivir both accessible and affordable to governments and patients around the world" and it plans to continue the production of the drug for "Europe, Asia and the developing world through at least 2022".
Supplied file photo shows anti-viral drug Remdesivir.
Close coordination of remdesivir manufacturing will be critical.
Remdesivir manufacturing relies on "scarce" raw materials that command their own "lengthy" production timelines, Gilead has said.
In a recent conversation with Hindustan Times, Dr. Srivari Chandrasekhar, the Director of IICT, said that Remdesivir has three KSMs - Pyrrole, Furan, and a Phosphate intermediate - and synthesizing them is a key step towards drug development.
Additionally, the company is in "advanced discussions" with the United Nations' UNICEF, explain, about how to provide medicine to low- and middle-income nations.
Indiana DNR: No 'Murder Hornets' reported in Indiana
Asian giant hornets are the largest hornet species in the world, growing up to 2 inches long with a three-inch wingspan. They're discouraging anyone from getting too close, as their stingers can penetrate even a beekeeper's suit.
Detail in new Kim Jong-un footage could explain his absence
But most of the deals have not been acted on by North Korea, with Pyongyang largely cutting off contact with Seoul . The military says in a statement South Korea fired two rounds in response after issuing a warning broadcast.
NBA Lottery, Combine Postponed
Note, the postponement of the Draft Combine & Draft Lottery likely means a postponement for the Draft as well. To this point, there has been no official decision on the 2020 NBA Draft, which is now scheduled for June 25.
Late Friday, the FDA gave the drug the emergency authorization based on controlled data showing the medicine could cut recovery time for hospitalized patients by 31%.
Two therapeutic drugs, Favipiravir and Remdesivir, will soon be approved in Japan for the fight against the Wuhan coronavirus (COVID-19).
USA biopharmaceutical firm Gilead Sciences Inc. said Monday it applied with the Japanese health ministry for approval to use its anti-viral drug remdesivir to treat new coronavirus patients, paving the way for its clearance as early as this week.
In that 1,063-patient trial, patients who received the Gilead drug recovered in 11 days compared with 15 days for those who received a placebo.
'This is very optimistic, the mortality rate trended towards being better in the sense of less deaths in the REM designate group.
The California company got US approval on Friday for use of remdesivir on an emergency basis.